Ann: IMM presents positive interim phase 2 TACTI-002 data at SITC, page-8

Further commentary:

Comparison to other therapies

The TACTI-002 ORR of 41% is higher than would be expected from a PD-L1 all comer (where patients have a range low to high PD-L1 TPS expression) trial of pembrolizumab given that PD-L1 expression TPS is predictive for response to pembrolizumab (the higher the better).

Typical ORR of pembrolizumab alone for patients with high (TPS ≥ 50%) PD-L1 expression in the tumour, is 39%. For patients with TPS ≥ 1% PD-L1 expression in the tumour the reported ORR is 27.2%. For pembrolizumab alone in patients with 1-49% PDL1 the reported ORR is 16.7%.2

The TACTI-002 ORR is also higher than would be expected with a doublet chemotherapy regimen where typically response rates of around 26% are reported.